Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal hepatitis B vaccination with topical imiquimod in prior vaccine non-responders
NL-OMON24074Recruiting
- Sponsor
- A.H.E. Roukens, MD L.G. Visser, MD, PhD
- Start
- May 2007
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imiquimod and hepatitis b vaccine recombinant in hepatitis B (HBV), sponsored by A.H.E. Roukens, MD L.G. Visser, MD, PhD. Primary endpoint: Serologic response after vaccination. Started May 2007; status: recruiting.
02
Drugs
imiquimodhepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NL-OMON24074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24074.